An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SMP-3124LP in Adults with Advanced Solid Tumors
A Phase 1/2 Study of SMP-3124LP in Adults with Advanced Solid Tumors
Tada Tomohiro
Sumitomo Pharma Co., Ltd.
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, Osaka 541-0045, Japan
+81-120-034-389
cr@sumitomo-pharma.co.jp
Product information center
Sumitomo Pharma Co., Ltd.
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, Osaka 541-0045, Japan
+81-120-034-389
cc@sumitomo-pharma.co.jp
Recruiting
Aug. 09, 2024
150
Interventional
single arm study
open(masking not used)
uncontrolled control
single assignment
treatment purpose
1) Histologically- or cytologically-confirmed cancer that is advanced, recurrent, or metastatic with the following origins, and whose disease progressed on standard therapy and for whom there are no alternative therapies that may confer overall survival benefit.
For Patients in the Dose Escalation Part:
a. Platinum-resistant ovarian cancer (PROC)
- Histologically diagnosed ovarian, fallopian tube, or primary peritoneal cancer, with predominantly high-grade (Grade 2 or 3) epithelial features (serous and clear cell)
- Platinum resistant is defined as relapsed within 6 months after the last dose of platinum-based therapy
b. Triple negative breast cancer (TNBC)
- ER- and PR-negative with HER2 negative
- HER2 negative is defined as one of the following: 0 or 1+ by IHC, or if IHC 2+, then in situ hybridization is negative per the ASCO-CAP HER2 guidelines
- ER- and PR-negative is defined as < 10% of cells expressing hormonal receptors by IHC, as per standard guidelines
c. Squamous cell carcinoma of the anus (SCCA)
- Patient with locally advanced ineligible for surgery is allowed.
d. Squamous cell carcinoma of the head and neck (SCCHN)
e. Non-small cell lung cancer (NSCLC: adenocarcinoma, large cell, and squamous cell carcinoma)
f. Uterine serous cancer (recurrent or persistent)
For Patients in the Dose Expansion Part:
g. Cohort A: PROC (same as above)
h. Cohort B: TNBC (same as above)
i. Cohort C: SCCA (same as above)
2) ECOG performance <= 2 at screening
3) Recovered from any prior treatment related toxicities
4) Adequate organ function as evidenced by:
Hemoglobin >= 9 g/dL (transfusion or use of erythropoietin to obtain this are not permitted)
Absolute neutrophil count >= 1500 uL (G-CSF or granulocyte macrophage colony-stimulating factor are not allowed to achieve this)
- Platelet count >= 100 x 10^3 /uL (platelet transfusion is not allowed to achieve this)
- Bilirubin <= 1.5 x ULN (or <= 3.0 x ULN if Gilberts syndrome)
- AST and ALT <= 3.0 x ULN (or <= 5 x ULN if the liver has tumor involvement)
- Calculated creatinine clearance >= 60 mL/min using Cockcroft-Gault formula
6) Patient is non-fertile or agrees to use adequate methods of contraception or agrees to refrain completely from heterosexual intercourse during the study and for 6 months (for female and male patients alike) after the last dose of study intervention
7) May be HIV positive if the following conditions are met:
- CD4 + T-cell count >= 350 cells/uL
- HIV viral load < 400 copies/ml prior to enrollment
- no history of acquired immune defficiency syndrome (AIDS) defining opportunistic infections
8) Known hepatitis B infection mush have negative serum HbsAg. Patients with known hepatitis C virus infection must have a viral load below the limit of quantification
- Japan sites only: HBc antibody or HBs antibody tests should be performed in HBsAg is negative. If HBc antibody or HBs antibody tests are positive, HBV DNA quantitative tests should be performed. to confirm that HBV DNA is negative
1) Patient has received prior treatment at any time with a cell cycle checkpoint inhibitor (eg, CHK1 and/or CHK2, WEE1, or ATR inhibition)
2) Patient has a known allergy or sensitivity to any component of SMP-3124LP, including the inactive ingredients
3) Received treatment with systemic anticancer therapy, radiotherapy, or investigational therapy within 14 days prior to Study Cycle 1 Day 1. (Palliative radiotherapy with a limited field of radiation within 2 weeks will be permitted.)
4) Patient has undergone a major surgical procedure <= 28 days, or minor surgical procedure <= 7 days, prior to Cycle 1 Day 1.
5) Patient has used strong CYP1A2 or 2D6 inhibitors within 14 days or 5 half lives, whichever occurs first prior to Cycle 1 Day 1.
6) Patient has central nervous system metastasis or leptomeningeal disease
7) Prior or concurrent malignancy whose natural history or treatment would have a significant potential to interfere with safety and efficacy assessments of the investigational regimen
8) Patient has an abnormal ECG that is clinically significant, including a corrected QT interval (corrected using Fridericias correction formula [QTcF]) > 470 msec; and/or a history of Torsade de Pointes)
9) Patient has a left ventricular ejection fraction < 45% by echocardiogram (ECHO)
10) Patient has clinically significant cardiac disease including heart failure (eg, New York Heart Association, Class III or IV)
11) Patient has an active, uncontrolled, bacterial, viral, or fungal infection requiring parenteral antimicrobial within 1 weeks prior to Cycle 1 Day 1
12) Patient is pregnant (as evidenced by a positive serum or urine pregnancy test) or is breastfeeding. Female breastfeeding patients may be enrolled if they interrupt breastfeeding. Breastfeeding should not be resumed for at least 6 months after the last dose of study drug.
- For sites in Japan only: In addition to the above, any patient deemed likely to be pregnant based on medical interview will be excluded from the study.
13) For patients with ovarian cancer:
a. History of bowel obstruction related to underlying disease within 3 months of C1D1
b. Has platinum-refractory disease. defined as progression during or within 3 months after receiving first line platinum-based chemotherapy.
14) Patient has any other medical or psychiatric condition that, in the opinion of the investigator, might interfere with their participation in the trial or interfere with the interpretation of trial results
15) Patient is taking a prohibited medication at baseline
16) For Japan sites only: Has any history or complication of interstitial lung disease.
18age old over
No limit
Both
Advanced solid tumors
Patients will receive SMP-3124LP continuous IV infusion every 2 weeks or every 3 weeks. The provisional dose levels of 20 mg/m2, 40 mg/m2, 60 mg/m2, 90 mg/m2, and 120 mg/m2. Intermediate dose levels may be added during dose escalation, based on the BLRM and EWOC principle.
Dose Escalation, Determine the Recommended Phase 2 Dose (RP2D), Assess the safety and tolerability
Dose Expansion, Evaluate preliminary antitumor activity:
